申请人:Hoffmann-La Roche Inc.
公开号:US04581172A1
公开(公告)日:1986-04-08
Pyrimidone derivatives of the formula ##STR1## wherein n is the integer 1 or 0; A.sup.1 and A.sup.2 are independently methylene or mono-lower alkyl or di-lower alkyl methylene; X is methylene, mono-lower alkyl or di-lower alkyl methylene, nitrogen or lower alkyl nitrogen; R is hydrogen or lower alkyl; and Y and Z taken together are the group .dbd.NR.sup.5, or R and Z taken together form a N--C--bond and Y is a group --N(H)R.sup.5 ; R.sup.1, R.sup.2 and R.sup.3 are hydrogen, lower alkyl or lower alkoxy, or R.sup.1 and R.sup.2 or R.sup.2 and R.sup.3 taken together are methylenedioxy or ethylenedioxy; R.sup.4 is hydrogen or lower-alkyl; R.sup.5 is phenyl or phenyl substituted by one or more of R.sup.6, R.sup.7 and R.sup.8 which, independently, are chlorine, fluorine, bromine, lower-alkyl or lower-alkoxy; and provided that at least one of the methylene groups A.sup.1 and A.sup.2 is mono-lower alkyl or di-lower alkyl methylene, when R.sup.4 is hydrogen and n is 0, and physiologically compatible salts thereof which have blood platelet aggregation-inhibiting activity or have activity on the circulatory system, are described. The compounds of formula I are obtained starting from corresponding chlorinated or brominated pyrimidone derivatives.
公式为##STR1##的嘧啶酮衍生物,其中n是整数1或0;A.sup.1和A.sup.2分别是亚甲基或单低烷基或双低烷基亚甲基;X是亚甲基、单低烷基或双低烷基亚甲基、氮或低烷基氮;R是氢或低烷基;Y和Z一起是群.dbd.NR.sup.5,或R和Z一起形成N-C-键,Y是群--N(H)R.sup.5;R.sup.1、R.sup.2和R.sup.3是氢、低烷基或低烷氧基,或R.sup.1和R.sup.2或R.sup.2和R.sup.3一起是亚甲二氧基或乙二氧基;R.sup.4是氢或低烷基;R.sup.5是苯基或苯基上取代一个或多个的R.sup.6、R.sup.7和R.sup.8,它们分别是氯、氟、溴、低烷基或低烷氧基;并且至少一个亚甲基A.sup.1和A.sup.2是单低烷基或双低烷基亚甲基时,当R.sup.4是氢且n为0时,以及其生理相容盐,具有抑制血小板聚集活性或对循环系统具有活性的物质被描述。从相应的氯化或溴化嘧啶酮衍生物出发,可以得到公式I的化合物。